Deciphera Pharmaceuticals, Inc. (DCPH)

14.75 -0.04 (-0.27%) At close: 04:00PM EDT

Deciphera Pharmaceuticals, Inc.

200 Smith Street
Waltham, MA 02451
United States
781 209 6400
https://www.deciphera.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 300

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Steven L. Hoerter	Pres, CEO & Director	1.01M	23.54k	1971
Dr. Daniel L. Flynn Ph.D.	Exec. VP, Chief Scientific Officer & Founder	645.61k	N/A	1955
Mr. Thomas Patrick Kelly J.D.	Exec. VP, CFO & Treasurer	644.12k	N/A	1971
Mr. Daniel C. Martin	Sr. VP & Chief Commercial Officer	611.24k	N/A	1975
Dr. Matthew L. Sherman M.D.	Exec. VP & Chief Medical Officer	725.85k	N/A	1956
Dr. Stephen B. Ruddy Ph.D.	Sr. VP & Chief Technical Officer	N/A	N/A	1964
Jennifer Larson	Sr. VP of Fin. & Investor Relations	N/A	N/A	N/A
Mr. Jeffrey M. Held J.D.	Sr. VP & Gen. Counsel	N/A	N/A	N/A
Ms. Lisa Amaya Price	Sr. VP & Chief HR Officer	N/A	N/A	N/A
Ms. Jama Pitman	Sr. VP of Regulatory, Quality & Portfolio Management	N/A	N/A	1979

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing medicines to improve the lives of cancer patients in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 in combination with RTK/RAS/MAP kinase signaling pathway inhibition to treat RAS/RAF mutant cancers. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Deciphera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 10. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.